During the 2016 American Society of Hematology (ASH) meeting, I was interviewed about how clinical pathways could be integrated as part of managing patients with chronic lymphocytic leukemia (CLL). Pathways are suggested to reduce variability in care but some oppose pathways as infringing on clinical decision-making. At the time of this OBR interview, I was VP and CMO at Cardinal Health Specialty Solutions.
Menu